Approximately 10% of all strains, both -lactamasepositive and -negative, are resistant to trimethoprim/ sulphamethoxazole.
Introduction
Over the last decade, Haemophilus influ e n z a e and M o r a xella catarrhalis have become increasingly recognized as s i g n i ficant respiratory tract pathogens among patients with community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) and sinusitis. 1 -5 The incidence of -lactamase-producing strains of H. influenzae and M. catarrhalis has become relatively common since they were first reported in the 1970s. [6] [7] [8] [9] Incidence rates of 10-40% have been reported for -lactamase-producing H. influenzae strains, [10] [11] [12] while -lactamase-producing M. catarrhalis strains were reported by The Alexander Project Collaborative Group in 1993 as having an incidence of 82% in western Europe and 92% in the USA.
1 3 -Lactamase-producing H. influ e n z a e strains are usually susceptible to cephalosporins, which are relatively stable to hydrolysis by the TEM-1 and ROB-1 enzymes. Strains of H. influenzae that are resistant to ampicillin and amoxycillin but are -lactamase-negative (BLNAR) have been reported, 14, 15 although the incidence of these strains has remained low. 16, 17 Resistance is caused by decreased permeability or altered penicillin binding proteins 15 and, as a result, these BLNAR H. influenzae strains are also usually resistant to first-generation cephalosporins.
MICs
MICs 
Bactericidal studies
Bactericidal studies were performed on two H. influenzae strains (one -lactamase-negative and one -lactamasepositive) in Mueller-Hinton broth plus 5% Fildes (peptic digest of sheep blood (Difco Laboratories)) at two different inoculum concentrations (10 6 and 10 7 cfu/mL), and at 2 ϫ, 4 ϫ and 8 ϫ MIC. Viable counts were performed at 0, 2, 4, 6 and 18 h after the addition of the antibiotic (levofloxacin, ofloxacin, ciprofloxacin or sparfloxacin) following serial dilution. Bacteria were counted after 24 h incubation at 37°C in air.
Results

Haemophilus influenzae
The results of the MIC determinations are listed in Table I For levofloxacin, ofloxacin, ciprofloxacin and sparfloxacin, the bactericidal effect was similar for -lactamase- 
Moraxella catarrhalis
The results of the MIC determinations are listed in Table  II 
Discussion
In this study, levofloxacin inhibited 100% of the H. influenzae and 90% of M. catarrhalis isolates at concentrations of 0.03 and 0.06 mg/L, respectively, regardless of -lactamase production. Our results, which showed that levofloxacin was twice as active as ofloxacin against both these species, are similar to those results obtained in other studies of respiratory pathogens. 22, 26, 27 Both ciprofloxacin and sparfloxacin were more active than levofloxacin against H. influenzae (one dilution) and M. catarrhalis (1-2 and 2-3 dilutions, respectively). The MIC 90 of sparfloxacin for H. influenzae (0.015 mg/L) is similar to that reported by Cohen et al. 28 (0.015 mg/L) but higher than that of Dabernat et al. 29 (0.007 mg/L), whilst the value for M. catarrhalis (0.015 mg/L) is lower than that reported by Cohen et al. 28 (0.03 mg/L) and Simor et al. 30 (0.125 mg/L). The MIC 90 of ciprofloxacin for H. influenzae (0.015 mg/L) is similar to that reported by Dabernat et al. 29 (0.015 mg/L) but lower than that of Cohen et al. 28 (0.03 mg/L), whilst the value for M. catarrhalis (0.06 mg/L) is similar to that reported by Cohen et al. 28 (0.06 mg/L) but lower than that of Simor et al. 30 (0.25 mg/L). Although sparfloxacin has good activity against respiratory pathogens, it is associated with a high incidence of adverse effects and this has led to restrictions on its use. 31, 32 C i p r o floxacin, despite its good activity against H. influ e n z a e and M. catarrhalis, has poor activity against Streptococcus pneumoniae compared with the newer fluoroquinolones such as levofloxacin and is therefore not suitable for either the empirical treatment of community-acquired lower respiratory tract infections or for the treatment of infections where S. pneumoniae is thought to be a possible cause. 33, 34 Levofloxacin has a favourable pharmacokinetic profile; 35 it is rapidly and completely absorbed following po administration, with a peak plasma concentration at steady state of approximately 5.7 mg/L within 1-2 h of po administration of a 500 mg dose to healthy volunteers. Furthermore, the absolute bioavailability of po levofloxacin is almost 100%, and the bioequivalence of the po and iv formulations allows for step-down or switch therapy from iv to po. An important aspect of levofloxacin's pharmacokinetic profile for the treatment of respiratory tract infections is its good penetration into the tissues and fluids of the respiratory tract. [36] [37] [38] [39] [40] Andrews et al. 36 showed that after a single po dosage of 500 mg, levofloxacin achieved clinically significant concentrations in bronchial biopsies, alveolar macrophages and epithelial lining fluid with mean site:serum ratios of between 0.8 and 11.6. The mean concentrations in all groups up to 6-8 h post-dose exceeded the MIC 90 s for the three major respiratory tract pathogens, S. pneumoniae, H. influenzae and M. catarrhalis, by at least two-fold. Comparing these results with a similar study of ciprofloxacin and temafloxacin, 41 the authors concluded that all three agents had similar site:serum ratios at 4 h post-dose with the exception of alveolar macrophages where the ratio for levofloxacin (9.1:1) was greater than that for ciprofloxacin (7.7:1) and temafloxacin (5.7:1).
In conclusion, the results of this study, showing the good in-vitro activity of levofloxacin in association with its pharmacokinetic profile and good penetration into the respiratory tract, indicate that levofloxacin may be effective in the treatment of respiratory tract infections caused by S. pneumoniae, H. influenzae and M. catarrhalis. 
